ClinicalTrials.Veeva

Menu
O

OnSite Clinical Solutions LLC | Charlotte, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Guselkumab
Semaglutide
BHV-7000
LY3298176
Rocatinlimab
Deudomperidone
Ecopipam
Ocrelizumab
Sisunatovir
BAY3427080

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 28 total trials

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (FOCUS)

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Placebo
Drug: Baricitinib

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Active, not recruiting
Colitis, Ulcerative
Biological: JNJ-78934804
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 3
Drug: Placebo

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Ustekinumab
Drug: Guselkumab Dose 3
Locations recently updated

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-cl...

Enrolling
Generalized Epilepsy
Drug: Placebo
Drug: BHV-7000

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

Enrolling
Focal Epilepsy
Drug: BHV-7000
Drug: Placebo

The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[...

Enrolling
Tourette Syndrome
Drug: Ecopipam

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling
Diabetic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 2

The purpose of this study is to learn about the safety and effects of sisunatovir. Sisunatovir is studied for the possible treatment of Respiratory S...

Enrolling
Respiratory Syncytial Virus Infection
Drug: Placebo
Drug: Sisunatovir

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Enrolling
Gout
Drug: Methotrexate
Biological: Pegloticase

This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to...

Enrolling
Insomnia
Drug: Daridorexant 10 mg
Drug: Daridorexant 25 mg

This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults...

Enrolling
Tourette Disorder
Drug: Ecopipam Hydrochloride

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy

Invitation-only
Focal Epilepsy
Drug: BHV-7000

The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with development...

Active, not recruiting
Developmental and Epileptic Encephalopathy
Lennox-Gastaut Syndrome
Drug: LP352, bexicaserin

The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE)...

Enrolling
Cutaneous Lupus Erythematosus (CLE)
Drug: Edecesertib
Drug: Edecesertib Placebo

Trial sponsors

Biohaven logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
Amgen logo
E
Novo Nordisk logo
Roche logo
AbbVie logo
Bayer logo
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems